CD20 drugs for Non-Hodgkin Lymphoma
3 tracked CD20 drugs in the Non-Hodgkin Lymphoma race. The class explanation lives on the CD20 page; the full indication pipeline across every mechanism is on the Non-Hodgkin Lymphoma page.
2 approved / phase 41 Phase 3
Head-to-head evidence: Obinutuzumab vs PF-05280586 · PF-05280586 vs Rituximab-abbs (Truxima)